Prognostic Stage IIA Breast Cancer AJCC v8 Terminated Phase 1 Trials for Talimogene laherparepvec (DB13896)

Also known as: Prognostic Stage 2A Breast Cancer AJCC v8

IndicationStatusPhase
DBCOND0109633 (Prognostic Stage IIA Breast Cancer AJCC v8)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04185311Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTreatment